The US Food and Drug Administration has approved Ogivri (trastuzumab-dkst), the first biosimilar for the treatment of certain breast and stomach cancers.
Indications: Ogivri (trastuzumab-dkst) was approved as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+).
Dosage and administration: For intravenous (IV) infusion only. Do not administer as an IV push or bolus.
Adjuvant Treatment of HER2-Overexpressing Breast Cancer
Administer at either:
- Initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel/carboplatin). 1 week after the last weekly dose of Ogivri, administer 6 mg/kg as an IV infusion over 30 to 90 minutes every 3 weeks to complete a total of 52 weeks of therapy, or
- Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks for 52 weeks.
Metastatic HER2-Overexpressing Breast Cancer
- Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions.
Adverse reactions: In adjuvant breast cancer, the most common adverse reactions (≥5%) are headache, diarrhea, nausea, and chills. In metastatic breast cancer, the most common adverse reactions (≥10%) are fever, chills, headache, infection, congestive heart failure, insomnia, cough, and rash.
US Food and Drug Administration. FDA approves first biosimilar for the treatment of certain breast and stomach cancers. FDA Web site. December 1, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587378.htm. Accessed December 6, 2017.
This Week's Must Reads
Second-Stage Duration & Outcomes After Prior CD, Obstet Gynecol; ePub 2018 Feb 5; Hehir, et al
Antihypertensive Med Use to Treat Preeclampsia, Obstet Gynecol; ePub 2018 Feb 5; Cleary, et al
Self-Reporting Hormonal Contraceptive Use & HIV, Contraception; ePub 2018 Feb 2; Pyra, et al
Cancer Tx and Infertility Risk in Women with PCOS, Fertil Steril; ePub 2018 Feb 7; Shandley, et al
ACOG Offers Guidance on Management of GDM, Obstet Gynecol; ePub 2018 Feb; ACOG, Turrentine
Must Reads in Breast Cancer
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al
FDA Approves Biosimilar for Certain Breast Cancers, FDA news release; 2017 Dec 1
Black-White Disparities in Breast Cancer Survival, J Clin Oncol; ePub 2017 Oct 16; Jemal, et al
Mammography Screening Patterns Evaluated, Womens Health Issues; ePub 2017 Sep 18; Jacobson, et al
FDA Approves New Mammography Device, FDA news release; 2017 Sep 1